BACKGROUND: Fatty acid synthase (FASN) is highly upregulated in human prostate carcinomas. Inhibition of FASN could arrest cell cycle and trigger apoptosis rapidly, implying the reliance of cancer cell survival on FASN. However, little is known about the effect of C75, a FASN inhibitor, and siFASN (that is, small interfering RNA targeted at FASN) on prostate cancer in living subjects. METHODS: We used C75 and siFASN to mediate the endogenous fatty acid metabolism in LNCaP human prostate cancer cells stably expressing herpes simplex virus type 1 thymidine kinase (HSV1-tk) and luciferase (luc) reporter genes, and assessed the effect of FASN blockade with different schedules of administration on tumor growth using noninvasive molecular imaging. RESULTS: FASN blockade exhibited the proliferative inhibition and induced G1-phase cell cycle arrest of LNCaP cells. For in vivo studies, the tumor growth inhibition by C75 (total 120 mg kg
INTRODUCTION
One of the metabolic alterations that commonly occur to fulfill the biosynthetic demands of proliferation in cancers is the overexpression of lipogenic enzymes. 1, 2 Fatty acid synthase (FASN) is the key cytosolic multifunctional enzyme that regulates de novo lipogenesis by catalyzing the terminal step of fatty acid synthesis. Many malignancies, compared with normal tissues, including colon, prostate, breast and lung carcinomas, express high levels of FASN, suggesting that FASN could be a potential target in cancer therapy. 3--5 FASN-specific small-molecule inhibitors and small interfering RNA (siRNA) have been used to interfere fatty acid synthesis in tumor cells to verify the biochemical link between lipogenesis and tumor progression. Cerulenin, the first identified inhibitor of FASN, is a natural antibiotic product of the fungus Cephalosporium ceruleans. 6 However, the clinical relevance of cerulenin is limited due to the chemical instability caused by a reactive epoxide group that may interact with other proteins. 7 C75, derived from cerulenin, is a semisynthetic and chemically stable inhibitor of FASN. Another alternative approach is to silence FASN genes of cancer cells with siRNA. The blockade of FASN induces the apoptosis of cancer cell lines in vitro and causes tumor growth delay in several tumor-bearing animal models, but relatively little is known about the inhibitory effect of C75 or siRNA targeted at FASN (siFASN) on prostate cancers in vivo. 8--12 In this study, we aimed to compare the therapeutic efficacy of C75 and siFASN with different schedules of administration in living subjects. We herein combined the LNCaP human prostate carcinoma-bearing mouse xenograft, which was transfected with dual reporter genes, HSV1-tk and luc, and multimodalities of molecular imaging for monitoring the tumor growth inhibition and the therapeutic efficacy evaluation.
MATERIALS AND METHODS
Tumor cell line and stable clone selection Human prostate carcinoma cell line LNCaP was obtained from the American Type Culture Collection (Manassas, VA, USA). Cells were maintained in RPMI1640 medium and supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin. All cultures were maintained at 37 1C in a humidified incubator containing 5% CO 2 . Standard cloning techniques were used to create a pC1-tk-IRES-luc vector as previously described. 13 LNCaP cells were transfected with pC1-tk-IRES-luc vector using jetPEI reagent (Polyplus, Illkirch, France) according to manufacturer's protocols, and renamed as LNCaP/tk-luc cell line. The expressions of both tk and luc genes were shown in the Supplementary Figure 1 .
Western blot
Lysates were subjected to SDS--polyacrylamide gel electrophoresis, then transferred to polyvinylidene difluoride membranes. The membranes were blocked with 5% nonfat milk for 1 h, and probed with anti-FASN (Cell Signaling, Danvers, MA, USA) and anti-b-actin (Novus, St Charles, MO, USA) antibodies at 4 1C overnight. Membranes were washed in Tris-Tween buffer saline, and incubated with horseradish peroxide-conjugated secondary antibodies (Kirkegaard & Perry Laboratories, Gaithersberg, MD, USA) at room temperature for 1 h. Final detection was achieved by using an ECL chemiluminescent detection system (Millipore, Billerica, MA, USA). ImageJ (National Institutes of Health, Bethesda, MD, USA) was used for the quantitative analysis.
Cell viability assay
The cytotoxicity effect of C75 (Sigma, St Louis, MO, USA) on LNCaP/tk-luc cells was determined by alamarBlue assay (Serotec, Oxford, UK). Briefly, 1 Â 10 4 cells per well were seeded in a 96-well plate 1 day before treatment with C75 for 24 h. After incubation, cells were exposed to alamarBlue for 4 h at 37 1C according to manufacturer's protocols. The absorbance at 570 and 600 nm was measured using ELISA reader (BioTek, Seattle, WA, USA).
Cell cycle analysis
In all, 1 Â 10 6 LNCaP/tk-luc cells treated with 5 mg ml À1 C75 were harvested at different time points, fixed with ice-cold 70% ethanol in phosphatebuffered saline for 24 h at À20 1C. Cells were stained with propidium iodide, assayed by a FACSCalibur flow cytometer and analyzed by CellQuest software (BD Biosciences, San Jose, CA, USA) for the cell cycle distribution.
Animal experiments
To generate a subcutaneous tumor model, 6-week-old male NOD/SCID mice were anesthetized by intraperitoneal (i.p.) injection of ketamine (100 mg kg À1 ) and xylazine (10 mg kg
À1
). In all, 6 Â 10 6 LNCaP/tk-luc cells mixed with 50% matrigel (BD Biosciences) were subcutaneously inoculated into the right lower limbs of mice. Tumor volume was measured twice a week with a caliper, and calculated according to the formula: length Â width Â height Â 0.523. When the tumor size reached 100 mm 3 , mice were i.p. administrated either with total C75 of 120 mg kg À1 for 4 weeks or 1.4 mg kg À1 of siRNA every other day for up to 16 days. Bioluminescent imaging and gamma scintigraphy were performed to evaluate the therapeutic efficacy as previously described. 12 All animal protocols were approved by the Animal Care and Use Committee of National Yang-Ming University.
Histopathology
The tumors were removed from mice, fixed with 4% formaldehyde solution and embedded in paraffin for sectioning. Hematoxylin and eosin staining was performed for all samples at the end of the treatments.
Statistics
Student's t-test was used to evaluate the significance between groups (*Po0.05; **Po0.01). Standard error of the mean was depicted as error bar in all figures.
RESULTS
C75 inhibited LNCaP/tk-luc cell proliferation by G1-phase arrest To assess the expression level of FASN, LNCaP/tk-luc cells were treated with C75 or were transiently transfected with siFASN. Western blot showed siFASN, as a positive control, markedly suppressed FASN expression, and the silencing of FASN lasted for at least 96 h. Cells treated with C75 (15 mg ml À1 ) for 24 h also revealed the moderate inhibition of FASN expression (31%; Figure 1a) . A dose-dependent cell survival was found with IC 50 of 15 mg ml À1 as shown in Figure 1b . LNCaP/tk-luc cells were arrested at G1 from 3 to 24 h post 5 mg ml À1 C75 treatments analyzed by flow cytometry as shown in Figure 1c .
The therapeutic evaluation of FASN blockade in vivo When tumor size reached 100 mm 3 , LNCaP/tk-luc tumor-bearing mice were i.p. injected with 15 mg kg À1 C75 twice a week or 30 mg kg À1 once a week for 4 weeks (i.e., the same total dose 120 mg kg À1 at the end of treatment for both groups). Figure 2a indicates that both the treatments resulted in a sustained tumor growth inhibition up to 70 days, confirming the antitumor effect of C75. On day 70 after tumor inoculation, the mean tumor volume of the control group (5% dimethyl sulfoxide) was 1430 mm 3 vs 330 mm 3 of the C75-treated group, corresponding to an 80% tumor inhibition effect. The body weight of mice was slightly, but insignificantly, changed (o20%) during the treatment, indicating no toxicity of C75 (Figure 2b ). The histopathology also revealed a marked depletion of cancer cells in both treatment groups (Figure 2c) .
The bioluminescent signal increased as tumors grew larger in the control group; however, the signal remained of the same intensity over times (from day 56 to day 73) in both treatment groups (Figure 3a) , confirming the tumor inhibition effect of FASN blockade. Gamma scintigraphy was performed 24 h after intravenous injection of 3.7 MBq per 0.1 ml 131 I-FIAU on day Figure 3b shows . We found 70% tumor growth inhibition in treated group as compared with that of the control (scramble siRNA; Figure 4a ). No general toxicity was observed judged from the body weight change during the treatment (Figure 4b ). Western blot confirmed that downregulation of FASN contributed to the growth inhibition of LNCaP/tk-luc tumors in vivo (Figure 4c ).
DISCUSSION
An increased de novo fatty acid synthesis, such as upregulation of FASN, is one of the distinguishing features that characterize cancer metabolism and benefit cancer cells in terms of growth advantage in the tumor environment with poor oxygenation and high acidity. 4, 14 High level of FASN has also been linked with poor prognosis and reduced disease-free survival in prostate cancer patients. 15, 16 It has been reported that overexpression of FASN induces transformation of immortalized prostate epithelial cells into invasive adenocarcinomas, and transgenic mice expressing FASN in the prostate develop intraepithelial neoplasia, suggesting that FASN has an important role in the development and progression of prostate cancer. 17 Therefore, this characteristic of cancer cells promises FASN to be a potential target for cancer therapy.
As other previous studies, our in vitro results reveal that FASN blockade with C75 could interfere with the proliferation and induce G1-phase cell cycle arrest of LNCaP tumor cells, which may involve the disturbance of membrane synthesis/lipid rafts assembly and the inhibition of PI3K-Akt pathway. 2, 18 FASN is also tightly regulated by growth factors and hormones, and its overexpression protects cells from apoptosis via stabilization of mitochondrial membrane potential. 17 Ample literatures have reported that increased epidermal growth factor/epidermal growth factor receptor and androgen-related signaling of tumor cells stimulate FASN transcription through the modulation of the sterol regulatory element-binding protein-binding site at the endogenous FASN promoter, leading to the resistance to chemotherapeutic agents that induce apoptosis. 4 Notably, it has been shown that FASN blockade with C75 augments the cytotoxicity of paclitaxel against breast cancer cells. Therefore, the combination of conventional chemotherapy with C75 may have potential for clinical application. 19 Although C75 is a cerulenin-derived semisynthetic FASN inhibitor lacking the reactive epoxy group, it may cause undesirable side effects, especially weight loss, by affecting food intake and energy expenditure in normal mice. 20 In our animal experiments, C75 treatment (total 120 mg kg À1 within 4 weeks) of human prostate cancer-bearing mice showed 80% tumor reduction without general toxicity, suggesting that this dosage was tolerable and had high toxicity to human prostate cancer cells in NOD/SCID mice. In addition, use of siRNA as an alternative agent to specifically target human FASN cDNA has been shown to induce apoptosis in LNCaP cells in vitro.
9 Therefore, the efficacy of this siRNA was also compared with that of C75 in vivo. Surprisingly, we found that C75 (30 mg kg À1 per week for 4 weeks) was superior to siFASN (1.4 mg kg À1 every alternate day up to 16 days) in tumor growth inhibition (80% vs 70%) as shown in the Supplementary  Figure 2 , suggesting that the stability and delivery of siRNA in vivo may be the major impediment in FASN-targeted therapy. Tumor growth monitoring with noninvasive molecular imaging in animal models offers high throughput and rapid assessment in cancer diagnosis and therapy. 21 In this study, both bioluminescent imaging and gamma scintigraphy showed that the lower photon intensity and less accumulation of 131 I-FIAU (about 40% of the control) in tumor cells were well correlated with the tumor growth inhibition after C75 treatment. On the other hand, acetate could be metabolized through the tricarboxylic acid cycle, and also be used as a substrate or a substrate precursor during lipogenesis. Imaging with positron emission tomography tracers such as 11 C-acetate has been evaluated to monitor the lipogenic phenotype. 22 In the future, this animal model combined with 11 C-actetate/positron emission tomography tracer will provide not only a better understanding of the endogeneous lipogenesis in prostate cancer progression, but also a unique opportunity to validate the effectiveness of novel combinational therapy for translational research. 
